Fortress Biotech, Inc.
FBIOHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Fortress Biotech, Inc. focuses on Biotechnology services and products. Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. With a market capitalization of $64.4M, it sits in micro-cap territory. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squam.
Market Cap
$64.4M
Beta
1.25
P/E (TTM)
0.70
P/E (Fwd)
-1.10
EPS (TTM)
$2.76
EPS (Fwd)
$-1.76
ROE
116.0%
ROA
-7.8%
Cash
$196.6M
Total Debt
$53.3M
Free CF
-$17.1M
52W Change
-24.9%
Annual Financials
Cash vs Debt
Where FBIO stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, FBIO finished 30.22% below its 150-day moving average ($2.68) and 35.07% below its 200-day moving average ($2.88). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is FBIO overbought or oversold?
At the October 20, 2026 close, FBIO's RSI(14) was 25.4, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $196.6M in cash and $53.3M in debt, FBIO maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$17.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of 116.0% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $75.7M to $63.3M.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Fortress Biotech, Inc. and its sector.